Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion

April 2024 | Volume 23 | Issue 4 | 255 | Copyright © April 2024


Published online March 20, 2024

Andreas Nikolis MD PhDa,b, Shannon Humphrey MDc, Jason K. Rivers MDd,e, Vince Bertucci MDf, Nowell Solish MDg,h, William McGillivray MDi, Kristy Bailey MDj, Nathan Rosen MDk, Andrei Metelitsa MDl,m, Annika Rugheimer MScn, Felipe Weinberg MDo, Inna Prygova MDn, Torun Bromee PhDn

aVictoria Park Medispas, Montreal, Quebec, Canada
bDivision of plastic surgery, McGill University, Montreal, Quebec, Canada 
cThe Centre for Clinical Trials Inc., Vancouver, British Columbia, Canada
dPacific Derm, Vancouver, British Columbia, Canada
eDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada
fBertucci MedSpa, Woodbridge, Ontario, Canada 
gSweat Clinics of Canada, Toronto, Ontario, Canada
hUniversity of Toronto, Toronto, Ontario, Canada 
iDr. William McGillivray Inc., Vancouver, British Columbia, Canada
jFCP Dermatology, Toronto, Ontario, Canada
kDermetics, Burlington, Ontario, Canada
lBeacon Dermatology, Calgary, Alberta, Canada
mDivision of Dermatology, University of Calgary, Calgary, Alberta, Canada
nGalderma, Uppsala, Sweden
oGalderma, Dallas, TX



Return to Social Engagements
The self-reported median time until subjects felt comfortable returning to social engagements was 19.0 hours (95% CI, 5.0, 26.0) after initial treatment and 7.0 hours (95% CI, 2.0, 20.0) after touch-up treatment.
 
Subject Photographs
Example photographs of a subject before and after treatment with HASHA are provided in Figure 4.

Safety
Safety results are reported for all subjects who were injected with HASHA (N=127), which included 25 subjects from the former control group who chose to receive treatment at month 12. Among the 123 HASHA-treated subjects who provided information in the 4-week subject diary, 100% reported at least one predefined, expected post-injection event (pain, tenderness, redness, bruising, swelling, or itching) after treatment. The most common diary-reported post-injection events after the initial injection were